A Pilot Study of Stereotactic Body Radiotherapy Combined with Pelvic Radiotherapy and GTVp Boost Based on Multiparameter Magnetic Resonance Image in Patients with High-risk Prostate Cancer

Overview

Journal Medicine (Baltimore)

Specialty General Medicine

Date 2023 Sep 29

PMID 37773877

Authors

Fang Wang

Jin Yao

Junru Chen

Hao Zeng

Xin Wang

Affiliations

Soon will be listed here.

Abstract

This pilot study aimed to explore the preliminary effects and safety of stereotactic body radiotherapy (SBRT) combined with preventive pelvic radiotherapy and primary gross tumor volumes (GTVp) boost in patients with high-risk prostate cancer based on multiparameter magnetic resonance image (mpMRI). Tumors were contoured as GTVp based on mpMRI. The prostate and proximal seminal vesicles were considered as the clinical target volume1. The pelvic lymphatic drainage area constituted clinical target volume 2. Radiation doses were 40Gy or 45Gy/5fractions to planning target volume of primary tumor, 37.5Gy/5f to prostate, seminal vesicle, and positive pelvic lymph nodes, and 25Gy/5f to pelvic synchronously. The treatment was delivered 3 times per week. Volumetric modulated arc radiotherapy and intensity-modulated radiotherapy were used to complete SBRT. The genitourinary (GU) and gastrointestinal (GI) toxicities were evaluated. Quality of life data was also captured. A total of 15 patients were enrolled in this study with a median age of 78 (56-87) from 2017 to 2020. All patients received SBRT. At 3 months after radiotherapy, the proportion of PSA < 0.006 ng/mL was 66.7% (10/15). The 2-year biochemical relapse-free survival was 93.3%. The incidence of grade 1 acute GU side effects was 80% (12/15); the incidence of acute grade 1 GI toxicity was 66.7% (10/15); and no grade 2 or higher acute GU and GI side effects was observed. Two patients presented with temporary late grade 2 GI toxicity. International Prostatic System Score increased rapidly after a transient increase at 1 week (P = .001). There were no significant differences in EORTC quality of life scores in all domains except global health status. In this pilot study, it was revealed that SBRT combined with preventive pelvic radiotherapy and GTVp boost based on mpMRI image was effective and well tolerated for patients with high-risk prostate cancer.

References

Fowler J . The radiobiology of prostate cancer including new aspects of fractionated radiotherapy. Acta Oncol. 2005; 44(3):265-76. DOI: 10.1080/02841860410002824. View

Aaronson N, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez N . The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993; 85(5):365-76. DOI: 10.1093/jnci/85.5.365. View

Tambas M, Agaoglu F, Iribas A, Guveli M, Dizdar Y, Okutan M . Conventionally Fractionationed Volumetric Arc Therapy versus Hypofractionated Stereotactic Body Radiotherapy: Quality of Life, Side Effects, and Prostate-Specific Antigen Kinetics in Localized Prostate Cancer. Value Health Reg Issues. 2016; 10:91-99. DOI: 10.1016/j.vhri.2016.08.001. View

Aluwini S, Pos F, Schimmel E, van Lin E, Krol S, van der Toorn P . Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial. Lancet Oncol. 2015; 16(3):274-83. DOI: 10.1016/S1470-2045(14)70482-6. View

Cellini N, Morganti A, Mattiucci G, Valentini V, Leone M, Luzi S . Analysis of intraprostatic failures in patients treated with hormonal therapy and radiotherapy: implications for conformal therapy planning. Int J Radiat Oncol Biol Phys. 2002; 53(3):595-9. DOI: 10.1016/s0360-3016(02)02795-5. View

Murthy V, Maitre P, Bhatia J, Kannan S, Krishnatry R, Prakash G . Late toxicity and quality of life with prostate only or whole pelvic radiation therapy in high risk prostate cancer (POP-RT): A randomised trial. Radiother Oncol. 2020; 145:71-80. DOI: 10.1016/j.radonc.2019.12.006. View

Xu N, Rossi P, Jani A . Toxicity analysis of dose escalation from 75.6 gy to 81.0 gy in prostate cancer. Am J Clin Oncol. 2010; 34(1):11-5. DOI: 10.1097/COC.0b013e3181cae8c6. View

Draulans C, van der Heide U, Haustermans K, Pos F, van der Voort van Zyp J, de Boer H . Primary endpoint analysis of the multicentre phase II hypo-FLAME trial for intermediate and high risk prostate cancer. Radiother Oncol. 2020; 147:92-98. DOI: 10.1016/j.radonc.2020.03.015. View

Boyer M, Papagikos M, Kiteley R, Vujaskovic Z, Wu J, Lee W . Toxicity and quality of life report of a phase II study of stereotactic body radiotherapy (SBRT) for low and intermediate risk prostate cancer. Radiat Oncol. 2017; 12(1):14. PMC: 5237336. DOI: 10.1186/s13014-016-0758-8. View

10.

Musunuru H, DAlimonte L, Davidson M, Ho L, Cheung P, Vesprini D . Phase 1-2 Study of Stereotactic Ablative Radiotherapy Including Regional Lymph Node Irradiation in Patients With High-Risk Prostate Cancer (SATURN): Early Toxicity and Quality of Life. Int J Radiat Oncol Biol Phys. 2018; 102(5):1438-1447. DOI: 10.1016/j.ijrobp.2018.07.2005. View

11.

Abdollah F, Cozzarini C, Sun M, Suardi N, Gallina A, Passoni N . Assessing the most accurate formula to predict the risk of lymph node metastases from prostate cancer in contemporary patients treated with radical prostatectomy and extended pelvic lymph node dissection. Radiother Oncol. 2013; 109(2):211-6. DOI: 10.1016/j.radonc.2013.05.029. View

12.

Helis C, Hughes R, Nieto K, Ufondu A, Daugherty E, Farris M . Adrenal SBRT: a multi-institutional review of treatment outcomes and toxicity. Clin Exp Metastasis. 2020; 37(5):585-592. DOI: 10.1007/s10585-020-10052-0. View

13.

Lee W, Dignam J, Amin M, Bruner D, Low D, Swanson G . Randomized Phase III Noninferiority Study Comparing Two Radiotherapy Fractionation Schedules in Patients With Low-Risk Prostate Cancer. J Clin Oncol. 2016; 34(20):2325-32. PMC: 4981980. DOI: 10.1200/JCO.2016.67.0448. View

14.

Royce T, Mavroidis P, Wang K, Falchook A, Sheets N, Fuller D . Tumor Control Probability Modeling and Systematic Review of the Literature of Stereotactic Body Radiation Therapy for Prostate Cancer. Int J Radiat Oncol Biol Phys. 2020; 110(1):227-236. PMC: 9445430. DOI: 10.1016/j.ijrobp.2020.08.014. View

15.

Aluwini S, Pos F, Schimmel E, Krol S, van der Toorn P, Jager H . Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial. Lancet Oncol. 2016; 17(4):464-474. DOI: 10.1016/S1470-2045(15)00567-7. View

16.

Widmark A, Gunnlaugsson A, Beckman L, Thellenberg-Karlsson C, Hoyer M, Lagerlund M . Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial. Lancet. 2019; 394(10196):385-395. DOI: 10.1016/S0140-6736(19)31131-6. View

17.

Wachter S, Wachter-Gerstner N, Bock T, Goldner G, Kovacs G, Fransson A . Interobserver comparison of CT and MRI-based prostate apex definition. Clinical relevance for conformal radiotherapy treatment planning. Strahlenther Onkol. 2002; 178(5):263-8. DOI: 10.1007/s00066-002-0907-x. View

18.

Eifler J, Feng Z, Lin B, Partin M, Humphreys E, Han M . An updated prostate cancer staging nomogram (Partin tables) based on cases from 2006 to 2011. BJU Int. 2012; 111(1):22-9. PMC: 3876476. DOI: 10.1111/j.1464-410X.2012.11324.x. View

19.

Hannan R, Tumati V, Xie X, Cho L, Kavanagh B, Brindle J . Stereotactic body radiation therapy for low and intermediate risk prostate cancer-Results from a multi-institutional clinical trial. Eur J Cancer. 2016; 59:142-151. DOI: 10.1016/j.ejca.2016.02.014. View

20.

McDonald A, Dobelbower M, Yang E, Clark G, Jacob R, Kim R . Prostate Stereotactic Body Radiation Therapy With a Focal Simultaneous Integrated Boost: Acute Toxicity and Dosimetry Results From a Prospective Trial. Adv Radiat Oncol. 2019; 4(1):90-95. PMC: 6349624. DOI: 10.1016/j.adro.2018.09.007. View